EMEA-002205-PIP01-17-M02
Key facts
| Invented name |
Sarclisa
|
| Active substance |
Isatuximab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0185/2021
|
| PIP number |
EMEA-002205-PIP01-17-M02
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Sanofi-Aventis Recherche & Développement
Tel. +33 169745695 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|